Vascular endothelial growth factor expression in untreated and androgen-deprived patients with prostate cancer

被引:19
作者
Aslan, G [1 ]
Cimen, S
Yorukoglu, K
Tuna, B
Sonmez, D
Mungan, U
Celebi, I
机构
[1] Dokuz Eylul Univ, Sch Med, Dept Urol, Izmir, Turkey
[2] Dokuz Eylul Univ, Sch Med, Dept Pathol, Izmir, Turkey
关键词
prostate; prostatic neoplasm; angiogenesis; VEGF; androgen deprivation therapy;
D O I
10.1016/j.prp.2005.07.003
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The aim of the study was to investigate immunohistochemically the expression of vascular endothelial growth factor (VEGF) in untreated and androgen-deprived patients with prostate cancer. The study included 20 patients with prostate cancer who had undergone transurethral prostatectomy due to infravesical obstruction. All patients had been receiving androgen deprivation therapy for at least 3 months. Transurethral prostatectomy specimens were examined for VEGF expression after androgen deprivation, and the biopsy samples of the same patients were used for the evaluation of VEGF expression before androgen deprivation. VEGF expression was analyzed using immunohistochemistry. Staining patterns determined by the staining scores were compared before and after treatment. The correlation of VEGF expression with PSA, Gleason score, and the percent change in PSA after treatment was also investigated. Eligible biopsy specimens were available in 15 of the 20 patients, allowing for the evaluation of VEGF expression before treatment. All prostate cancer specimens were positive. VEGF was localized mainly in the cytoplasm or on the membrane of carcinoma cells. Staining was strong in 86.7% of patients before androgen deprivation. Heterogeneous staining (strong in 25%, moderate in 35%, and weak in 40%) was observed after treatment. Staining scores were significantly higher in patients before androgen deprivation and showed a significant decrease after androgen deprivation (P = 0.007). Tumor staining correlated with Gleason score. No significant correlation was determined between VEGF expression and pre-treatment PSA and percent change of PSA after treatment. Immunohistochemical results indicate that VEGF expression is downregulated by androgen deprivation therapy. VEGF may be a potential target for therapeutic intervention in prostate cancer. (c) 2005 Elsevier GmbH. All rights reserved.
引用
收藏
页码:593 / 598
页数:6
相关论文
共 33 条
[1]  
Borgström P, 1998, PROSTATE, V35, P1
[2]  
BRAWER MK, 1994, CANCER, V73, P678, DOI 10.1002/1097-0142(19940201)73:3<678::AID-CNCR2820730329>3.0.CO
[3]  
2-6
[4]  
Burchardt M, 2000, PROSTATE, V43, P184, DOI 10.1002/(SICI)1097-0045(20000515)43:3<184::AID-PROS4>3.0.CO
[5]  
2-6
[6]   Angiogenesis and prostate cancer: In vivo and in vitro expression of angiogenesis factors by prostate cancer cells [J].
Ferrer, FA ;
Miller, LJ ;
Andrawis, RI ;
Kurtzman, SH ;
Albertsen, PC ;
Laudone, VP ;
Kreutzer, DL .
UROLOGY, 1998, 51 (01) :161-167
[7]   Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells [J].
Ferrer, FA ;
Miller, LJ ;
Andrawis, RI ;
Kurtzman, SH ;
Albertsen, PC ;
Laudone, VP ;
Kreutzer, DL .
JOURNAL OF UROLOGY, 1997, 157 (06) :2329-2333
[8]   A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride [J].
Foley, SJ ;
Soloman, LZ ;
Wedderburn, AW ;
Kashif, KM ;
Summerton, D ;
Basketter, V ;
Holmes, SAV .
JOURNAL OF UROLOGY, 2000, 163 (02) :496-498
[9]   Castration-induced reduction of vascular endothelial growth factor expression in benign human prostate tissue is lost in advanced prostate cancer [J].
Häggström, S ;
Stattin, P ;
Wikström, P ;
Bergh, A ;
Damber, JE .
BJU INTERNATIONAL, 2001, 88 (01) :110-116
[10]  
Häggström S, 1998, PROSTATE, V36, P71